Phase II trial of CPX-351 (cytarabine:daunorubicin) liposome injection in patients with acute myeloid leukemia >60 years of age who have not been treated with intensive chemotherapy.
Ellen K. Ritchie(Cornell University), Gail J. Roboz(Cornell University), Tania J. Curcio(Cornell University), Sumaiya Miah(Cornell University), Pinkal Desai(NewYork–Presbyterian Hospital), Jeff Ball(Cornell University), Sang‐Min Lee(Seoul National University), Michael S. Samuel(Cancer Research UK Scotland Institute)
Cited by 0
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k